Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sri Harsha Tella

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
BMJ Case Reports|August 21, 2014
Disseminated histoplasmosis in an HIV patient with CD4 count of 1 cell/µLSri Harsha Tella, Ahmed Abuzaid
Expert Opinion on Pharmacotherapy|October 18, 2022
An evaluation of ivosidenib for the treatment of <i>IDH1</i>-mutant cholangiocarcinomaSri Harsha Tella, Amit Mahipal
Cureus|December 2, 2015
Thyrotoxic Periodic Paralysis: An Underdiagnosed and Under-recognized ConditionSri Harsha Tella, Anuhya Kommalapati
Hepatobiliary Surgery and Nutrition|June 9, 2020
The future of adjuvant therapy in ampullary cancer: should we offer it to our patients?Sri Harsha Tella, Amit Mahipal
Expert Opinion on Pharmacotherapy|September 26, 2014
Efficacy of desvenlafaxine succinate for menopausal hot flashesSri Harsha Tella, John Christopher Gallagher
Clinical Obstetrics and Gynecology|September 17, 2013
Controversies in osteoporosis management: antiresorptive therapy for preventing bone loss: when to use one or two antiresorptive agents?J Christopher Gallagher, Sri Harsha Tella
Expert Opinion on Pharmacotherapy|October 8, 2013
Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopauseSri Harsha Tella, John Christopher Gallagher
Expert Opinion on Drug Safety|December 10, 2014
DPP-4 inhibitors: focus on safetySri Harsha Tella, Marc S Rendell
European Journal of Clinical Pharmacology|September 11, 2014
Biological agents in management of osteoporosisSri Harsha Tella, J Christopher Gallagher
The Journal of Steroid Biochemistry and Molecular Biology|November 2, 2013
Prevention and treatment of postmenopausal osteoporosisSri Harsha Tella, J Christopher Gallagher
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
BMJ Case Reports|August 21, 2014
Disseminated histoplasmosis in an HIV patient with CD4 count of 1 cell/µLSri Harsha Tella, Ahmed Abuzaid
Expert Opinion on Pharmacotherapy|October 18, 2022
An evaluation of ivosidenib for the treatment of <i>IDH1</i>-mutant cholangiocarcinomaSri Harsha Tella, Amit Mahipal
Cureus|December 2, 2015
Thyrotoxic Periodic Paralysis: An Underdiagnosed and Under-recognized ConditionSri Harsha Tella, Anuhya Kommalapati
Hepatobiliary Surgery and Nutrition|June 9, 2020
The future of adjuvant therapy in ampullary cancer: should we offer it to our patients?Sri Harsha Tella, Amit Mahipal
Expert Opinion on Pharmacotherapy|September 26, 2014
Efficacy of desvenlafaxine succinate for menopausal hot flashesSri Harsha Tella, John Christopher Gallagher
Clinical Obstetrics and Gynecology|September 17, 2013
Controversies in osteoporosis management: antiresorptive therapy for preventing bone loss: when to use one or two antiresorptive agents?J Christopher Gallagher, Sri Harsha Tella
Expert Opinion on Pharmacotherapy|October 8, 2013
Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopauseSri Harsha Tella, John Christopher Gallagher
Expert Opinion on Drug Safety|December 10, 2014
DPP-4 inhibitors: focus on safetySri Harsha Tella, Marc S Rendell
European Journal of Clinical Pharmacology|September 11, 2014
Biological agents in management of osteoporosisSri Harsha Tella, J Christopher Gallagher
The Journal of Steroid Biochemistry and Molecular Biology|November 2, 2013
Prevention and treatment of postmenopausal osteoporosisSri Harsha Tella, J Christopher Gallagher
Pageof 9